Article
FDA panel expresses concern over OTC OAB patch
Merck has confirmed that the FDA Nonprescription Drug Advisory Committee proposed that the FDA consider labeling modifications as part of its review of oxybutynin transdermal system (Oxytrol) as an over-the-counter treatment for overactive bladder in women.
Related Videos
Prostate cancer screening: Expert weighs in after Biden's diagnosis
Sarah Razavi, MD, discusses the physical toll of ureteroscopy on urologists
Clinical Outcomes of Ultra-Low PSA Responses in Patients With mHSPC Receiving Darolutamide Plus ADT
Treatment or Lack of Treatment of Small Renal Masses
The current treatment landscape of mHSPC
Strengths and Weaknesses of Imaging Modalities in ccRCC
BPH: Strategies for Guiding Patients From Medication to Intervention
Representation of Black men with mHSPC in clinical trials
Post Hoc Analysis of ARANOTE; Ultra-Low PSA Responses
Study results affirm effectiveness of evolving prostate cancer therapies
Related Content
